This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Gynecology  • Women's Health, Other  • Oncology  • Cervical Cancer  • Patient-Physician Communication  • Alert me on articles by topic

George F. Sawaya, MD, Discussant

JAMA. 2005;294:2210-2218.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

DR REYNOLDS: Ms G is a 21-year-old woman with a history of abnormal Papanicolaou (Pap) tests.

Ms G first became sexually active at age 19. That year, she had her first gynecologic examination when she visited a doctor to ask for an oral contraceptive pill prescription. Her examination and cytology test were normal. She had annual Pap screening until age 21, when her cytology test (conventional) showed atypical squamous cells of undetermined significance (ASC-US). Her clinician, a nurse practitioner at student health, recommended a repeat cytology test in 6 months. Her repeat test again showed ASC-US, and she was referred to a gynecologist who performed a colposcopy.

On colposcopy, the entire squamocolumnar junction could be seen and her cervix showed grade 1 acetowhite changes. Biopsy revealed metaplasia. A liquid-based cytology test done at the time of the colposcopy was normal. . . . [Full Text of this Article]

MS G: HER VIEW

AT THE CROSSROADS: QUESTIONS FOR DR SAWAYA

Cervical Cancer and ASC-US

Beginning Cervical Cancer Screening

Liquid-Based vs Conventional Cytology

Managing ASC-US: Colposcopy vs Repeat Cytology vs HPV DNA Testing

RECOMMENDATIONS FOR MS G

QUESTIONS AND DISCUSSION

AUTHOR INFORMATION

Author Affiliation: Dr Sawaya is Associate Professor, Department of Obstetrics, Gynecology and Reproductive Sciences; Department of Epidemiology and Biostatistics, University of California, San Francisco; and Director of the Cervical Dysplasia Clinic at San Francisco General Hospital.

RELATED LETTERS

Tests for Atypical Squamous Cells of Undetermined Significance
Brian Budenholzer
JAMA. 2006;295(11):1247.
EXTRACT | FULL TEXT  

Tests for Atypical Squamous Cells of Undetermined Significance—Reply
George F. Sawaya
JAMA. 2006;295(11):1247-1248.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Screen-and-Treat Approaches for Cervical Cancer Prevention in Low-Resource Settings: A Randomized Controlled Trial
Lynette Denny, Louise Kuhn, Michelle De Souza, Amy E. Pollack, William Dupree, and Thomas C. Wright, Jr
JAMA. 2005;294(17):2173-2181.
ABSTRACT | FULL TEXT  

Feasibility of Management of High-Grade Cervical Lesions in a Single Visit: A Randomized Controlled Trial
Wendy R. Brewster, F. Allan Hubbell, Joan Largent, Argyrios Ziogas, Fritz Lin, Susan Howe, Theodore G. Ganiats, Hoda Anton-Culver, and Alberto Manetta
JAMA. 2005;294(17):2182-2187.
ABSTRACT | FULL TEXT  

Cervical Cancer Prevention: Making Programs More Appropriate and Pragmatic
Paul D. Blumenthal and Lynne Gaffikin
JAMA. 2005;294(17):2225-2228.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adding Human Papillomavirus Testing to Cytology for Primary Cervical Cancer Screening: Shooting First and Asking Questions Later
Sawaya
ANN INTERN MED 2008;148:557-559.
FULL TEXT  

Evidence-Based Medicine Versus Liquid-Based Cytology
Obstet Gynecol 2008;111:2-3.
FULL TEXT  

Trials That Matter: Liquid-Based Cervical Cytology: Disadvantages Seem to Outweigh Advantages
Sawaya and Sox
ANN INTERN MED 2007;147:668-669.
FULL TEXT  

Tests for Atypical Squamous Cells of Undetermined Significance
Budenholzer
JAMA 2006;295:1247-1247.
FULL TEXT  

Cervical Cancer Prevention: Making Programs More Appropriate and Pragmatic
Blumenthal and Gaffikin
JAMA 2005;294:2225-2228.
FULL TEXT